Severe chronic active hepatitis induced by UFTR containing tegafur and uracil.
A 77-year-old female patients developed severe hepatic injury after the administration of UFTR, which contains tegafur and uracil, for postoperative chemotherapy of colon cancer. Liver damage was recognized 10 months after its administration. Serum markers for viral hepatitis and various autoantibodies were negative. The wedged biopsied liver specimen revealed advanced chronic active hepatitis with periportal confluent necrosis, marked intralobular spotty necrosis, and significant proliferation of pseudo-bile ductules. Although the cessation of the drug and conservative therapies improved hepatic function, an accidental readministration of UFTR caused her severe hepatic damage again. These findings suggest that liver injury in the present case was caused by UFTR. Histological findings were unique. Although tegafur is known to worsen hepatic function when given to patients with liver cirrhosis, UFTR may also cause severe hepatic injury in those without preexisting liver disease.
Kobayashi
F
F
Department of Internal Medicine, Yokosuka Kyosai Hospital, Kanagawa, Japan.
Ikeda
T
T
Sakamoto
N
N
Kurosaki
M
M
Tozuka
S
S
Sakamoto
S
S
Fukuma
T
T
Marumo
F
F
Sato
C
C
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D056487:Chemical and Drug Induced Liver Injury, Chronic; D003110:Colonic Neoplasms / Q000188:drug therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects*; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects*
D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil